Document:

EX-10.57

Exhibit 10.57

PROSIDION LIMITED

SCIENTIFIC ADVISORY BOARD AND CONSULTING AGREEMENT

     This Scientific Advisory Board and Consulting Agreement (this “Agreement”) is made and
entered into as of December 16, 2008, and effective as of January 1, 2009 (the “Effective Date”),
by and between Prosidion Limited, a company registered in England and Wales under registered number
4600121 with its registered office at Watlington Road, Oxford, UK OX4 6LT (the “Company”) and Dr.
Daryl Granner, Professor, an individual with an address of 707 Light Hall, Vanderbilt University
Medical Centre, Nashville, Tennessee 37232, USA (“Consultant ”).

Recitals

     The Company desires to retain distinguished physicians as members of the Company’s
Scientific Advisory Board (the “Board”) to advise the Company with respect to new and existing
compounds and products in research and development in the field of diabetes, metabolic diseases and
obesity. The Company and Consultant desire to enter into this Agreement in order to set forth the
basis on which Consultant will serve as a member of the Board and provide consulting services to
the Company in relation thereto.

Agreement

     In consideration of the mutual covenants set forth below, the parties hereby agree as
follows:

	 	1.	 	Engagement of Services.

          (a) Consultant shall serve as chairman of the Board and will provide ongoing advice to the
Company with respect to research, development and marketing of diabetes, metabolic diseases and
obesity products. Such services shall be performed as requested by the Company, at such places and
times as shall be mutually agreeable to the Company and Consultant. It is anticipated that the
Board will meet in person on four (4) occasions per year. In addition, Consultant shall be
available to consult with the Company with respect to diabetes, metabolic diseases and obesity
opportunities, over the telephone and in person, as requested by the Company and at mutually
agreeable times and locations. Services performed pursuant to this Agreement shall be performed at
such times as shall not conflict with Consultant’s obligations to Consultant’s primary employer or
other third parties for whom Consultant provides consulting services. Consultant shall have no
minimum consulting obligation hereunder.

          (b) Consultant agrees to perform all services for the Company hereunder
faithfully, diligently and to the best of Consultant’s skill and ability.

1

 

          (c) Consultant represents that Consultant has the authority to enter into this
Agreement and that Consultant’s performance of the terms of this Agreement and service as a member
of the Board and a consultant to the Company do not and will not breach any obligation or agreement
of Consultant to Consultant’s primary employer or any other third party.

          (d) Consultant understands and acknowledges that the payments Consultant will
receive pursuant to Section 2 below are intended solely to compensate Consultant for the services
Consultant will provide hereunder. Such payments shall in no way influence Consultant’s
professional judgment in performing services hereunder or otherwise.

	 	2.	 	Compensation.

          (a) In consideration of Consultant’s services hereunder, the Company shall pay to Consultant a
fee at the rate of seventy-five thousand U.S. dollars ($75,000) per annum pro rated for the term of
the Agreement (i.e., six thousand two hundred fifty U.S. dollars (US $6,250) per calendar month) on
the understanding that it is anticipated that the Company shall hold approximately four (4) Board
meetings per annum and that ad hoc Board meetings may from time to time be convened. Fees shall be
payable to Consultant on a monthly basis in arrears.

          (b) The Company will reimburse Consultant for travel and other out-of-pocket
expenses reasonably and properly incurred by Consultant in the course of performing services under
this Agreement; provided, however, that Consultant provides the Company with appropriate receipts
and other relevant documentation for all such costs as part of any request by Consultant for
reimbursement. Notwithstanding the foregoing, Consultant shall obtain the prior written consent of
the Company for any expenses that will exceed, in the aggregate, more than $2,500.

	 	3.	 	Independent Contractor.

          It is understood and agreed that Consultant is an independent contractor and not an employee
of the Company. Consultant has no authority to obligate the Company by contract or otherwise and
shall in no way represent Consultant to be an employee or officer of the Company. Consultant will
not be eligible for any employee benefits, nor will the Company make deductions from Consultant’s
fees for any taxes, national insurances or VAT payments. Taxes, national insurance and VAT payments
shall be the sole responsibility of Consultant.

2

 

	 	4.	 	Additional Activities.

          (a) The Company acknowledges that Consultant has other employment and consulting obligations,
and that these obligations may take priority over the obligations Consultant has to the Company by
reason of this Agreement.

          (b) The Company’s policy is that persons who serve as principal investigators
for clinical trials sponsored by the Company may not hold stock or other equity interests in the
Company. Consultant agrees that if in the future Consultant becomes a principal investigator or
otherwise plays a significant role in any clinical trial sponsored by the Company, Consultant will
comply with this policy.

          (c) In order to avoid conflicts concerning ownership of intellectual property,
Consultant will not conduct work for the Company on the premises of Consultant’s employer or with
its facilities unless there is a written agreement covering such work between the Company and such
institution.

	 	5.	 	Proprietary Information.

          (a) During the course of Consultant’s services hereunder, the Company may disclose, or
Consultant may otherwise have access to, Proprietary Information of the Company. For purposes of
this Agreement, “Proprietary Information” shall mean information relating to the Company’s research
and development programs and results, therapeutic candidates and products, clinical and preclinical
data, Inventions (as defined in Section 7), trade secrets, business strategy, patent rights,
licenses, product and marketing strategy and materials, market data, personnel, consultants,
suppliers, manufacturers, licensors, licensees, partners, affiliates, customers, potential
customers or others, or other matters related to and treated confidentially by the Company.

          (b) Proprietary Information subject to this Section 5 shall not include
information that: (i) is or later becomes available to the public through no breach of this
Agreement by Consultant; (ii) is obtained by Consultant from a third party who had the legal right
to disclose the information to Consultant; (iii) is already in the possession of Consultant on the
date this Agreement becomes effective and was not Proprietary Information or subject to other
restrictions on disclosure as of that date as shown by written records predating the date it was
obtained under this Agreement; or (iv) is required to be disclosed by law, government regulation,
or court order, provided that Consultant gives the Company prompt notice of such disclosure
requirement and assists the Company so as to enable the Company to seek limitations or exemptions
from such disclosure requirement.

          (c) Consultant acknowledges that the protection of Proprietary Information is
necessary to conduct the Company’s business, and the Company is and shall at all times remain the
sole owner of the Company’s Proprietary Information.

3

 

          (d) During the term of this Agreement and for five (5) years thereafter,
Consultant will keep in confidence and trust all Proprietary Information, and shall not use or
disclose such Proprietary Information, except as such use may be required in performing services as
a consultant to the Company.

	 	6.	 	Nondisclosure of Third-Party Information.

          Consultant understands that the Company has received and in the future will receive from third
parties information that is confidential or proprietary (“Third-Party Information”), subject to a
duty on the part of the Company to maintain the confidentiality of such information and to use it
only for certain limited purposes. During the term of this Agreement and thereafter, Consultant
will hold Third-Party Information which Consultant learns in connection with Consultant’s services
hereunder in the strictest confidence and will not disclose or use such Third-Party Information
except as permitted by the agreement between the Company and such third party, unless expressly
authorized to act otherwise by the Company.

	 	7.	 	Rights to Inventions and Intellectual Property.

          (a) In connection with Consultant’s services hereunder, or by use of the resources of the
Company, Consultant may produce, develop, create or invent Inventions and Intellectual Property
(each as defined below) related to the business of the Company. Consultant shall maintain and
furnish to the Company complete and current records of all such Inventions and Intellectual
Property and disclose to the Company in writing any such Inventions and Intellectual Property.
Consultant agrees that all such Inventions and Intellectual Property are and shall be the exclusive
property of the Company, and that the Company may use or pursue them without restriction or
additional compensation. Consultant: (i) hereby assigns, sets over and transfers to the Company all
of Consultant’s right, title and interest in and to such Inventions and Intellectual Property;
(ii) agrees that Consultant and Consultant’s agents shall, during and after the period Consultant
is retained by the Company, cooperate fully in obtaining patent, trademark, service mark, copyright
or other proprietary protection for such Inventions and Intellectual Property, all in the name of
the Company (but only at Company expense), and, without limitation, shall execute all requested
applications, assignments and other documents in furtherance of obtaining such protection or
registration and confirming full ownership by the Company of such Inventions and Intellectual
Property; and (iii) shall, upon termination or expiration of this Agreement, provide to the Company
in writing a full, signed statement of all Inventions and Intellectual Property in which Consultant
participated prior to such termination or expiration.

          (b) For purposes of this Agreement, “Intellectual Property” shall mean any
Invention, writing, trade name, trademark, service mark or any other material registered or
otherwise protected or protectable under state, federal, or foreign patent, trademark, copyright,
or similar laws; and “Inventions” shall mean ideas, discoveries, inventions, developments and
improvements, whether or not reduced to practice and whether or not

4

 

patentable or otherwise within the definition of Intellectual Property.

          (c) Consultant acknowledges that the protection of Intellectual Property is
necessary to conduct the Company’s business, and the Company is and shall at all times remain the
sole owner of the Company’s Intellectual Property.

	 	8.	 	Term and Termination.

          (a) This Agreement shall commence on the Effective Date and be effective until 31st
December 2009, unless the Agreement is extended beyond this term by prior written agreement of the
parties; in the absence of which this Agreement and any obligations contained herein or understood
between the parties in relation to membership on the Board and other advisory services shall
forthwith lapse.

          (b) Either party can terminate this Agreement at any time upon sixty (60) days
prior notice in which event this Agreement and any obligations contained herein or understood
between the parties in relation to membership on the Board shall forthwith lapse and only those
fees payable to the date of termination shall be payable by the Company.

          (c) The parties shall mutually agree in writing with respect to any extension of
the term hereof.

	 	9.	 	Effect of Termination.

          Upon the expiration or termination of this Agreement, each party shall be released from all
obligations and liabilities to the other occurring or arising after the date of such expiration or
termination, except that expiration or termination of this Agreement shall not relieve (i)
Consultant of Consultant’s obligations under Sections 5, 6 and 7 hereof; (ii) the Company of its
obligations to reimburse Consultant for expenses under Section 2(b) hereof; or (iii) Consultant or
the Company from any liability arising from any breach of this Agreement. Upon expiration or
termination of this Agreement for any reason whatsoever, Consultant shall promptly surrender and
deliver to the Company all documents and other materials pertaining to Consultant’s work with the
Company, and any documents or other materials (including reproductions thereof) containing any
Proprietary Information.

	 	10.	 	Assignment.

          The rights and liabilities of the parties hereto shall bind and inure to the benefit of their
respective successors, heirs, executors and administrators, as the case may be; provided, however,
that because the Company has specifically contracted for Consultant’s services, Consultant may not
assign or delegate Consultant’s obligations under this Agreement, either in whole or in part,
without the prior written consent of the Company.

5

 

	 	11.	 	Legal and Equitable Remedies.

          Since Consultant’s services are personal and unique and since Consultant may have access to
Proprietary Information, the Company shall have the right to enforce this Agreement and any of its
provisions by injunction, specific performance or other equitable relief without prejudice to any
other rights and remedies that the Company may have for a breach of this Agreement.

	 	12.	 	Governing Law; Severability.

          This Agreement shall be governed by the laws of England and Wales and the parties hereby
submit to the exclusive jurisdiction of the English courts. If any provision of this Agreement is
found by a court of competent jurisdiction to be unenforceable, that provision shall be severed and
the remainder of this Agreement shall continue in full force and effect.

	 	13.	 	Complete Understanding; Modification.

          This Agreement constitutes the final, exclusive and complete understanding and agreement of
the parties hereto and supersedes all prior understandings and agreements. Any waiver, modification
or amendment of any provision of this Agreement shall be effective only if in writing and signed by
the parties hereto.

	 	14.	 	Notices.

          (a) All notices, requests, consents and other communications hereunder shall be in writing,
addressed to the receiving party’s address as set forth below or to such other address as a party
may designate by notice hereunder, and either (i) delivered by hand, (ii) sent by overnight
courier, or (iii) sent by registered or certified mail, return receipt requested, postage prepaid.

          (b) All notices, requests, consents and other communications hereunder shall be
deemed to have been given either (i) if by hand, at the time of the delivery thereof to the
receiving party at the address of such party set forth above, (ii) if sent by overnight courier, on
the next business day following the day such notice is delivered to the courier service, or
(iii) if sent by registered or certified mail, on the third business day following the day such
mailing is made.

	 	15.	 	Counterparts.

          This Agreement may be executed by the parties hereto on separate counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same
instrument.

6

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
written above.

	 	 	 
	PROSIDION LIMITED

	 	CONSULTANT
	 
	 	 
	/s/ Anker Lundemose

	 	/s/ Daryl Granner
	 

	 	 
	By: Dr. Anker Lundemose

	 	Dr. Daryl Granner
	Chief Executive Officer
	 	 

7EX-10.62

Exhibit 10.62

Compensatory Arrangements for Non-Employee Directors

     OSI Pharmaceuticals, Inc. (“OSI” or the “Company”) compensates its non-employee directors for
service on the Company’s Board of Directors (the “Board”) with both cash and equity compensation
upon initial election and annual election to the Board. In 2007, the Compensation Committee of the
Board (the “Committee”) engaged Radford Consulting (“Radford”), its independent compensation
consultant, to evaluate OSI’s Board compensation. Upon evaluation and review, Radford, the
Committee and the Board determined that the compensation structure should be revised in order to
(1) better align Board members’ compensation with their responsibilities and (2) align Board
compensation with the more typical practices at peer companies. OSI’s former Board compensation
provided greater compensation upon initial election to the Board as opposed to subsequent
elections. Pursuant to Radford’s recommendation and the Committee’s and Board’s review, the Board
approved changes to the compensation structure, effective beginning the date of the Company’s 2008
Annual Meeting of Stockholders (the “2008 Annual Meeting”), (1) to compensate the Chairs of Board
committees and service on more than one committee and (2) in general, to decrease the amount of
compensation upon initial election to the Board and increase the amount of annual compensation. In
order to be more equitable and avoid any windfalls, the Board approved a requirement that all
members of the Board elected to the Board prior to the 2008 Annual Meeting must serve at least
three years on the Board before they are eligible to receive the revised annual equity grants
described below. Set forth below is a summary of the current Board compensation.

Annual Retainer Fee:

     Each of the non-employee directors of the Company receives an annual cash retainer fee as set
forth in the table below.

	 	 	 	 	 
	Baseline
Cash Compensation
	 	 	 	 
	Board Member Retainer Fee
	 	$	50,000	 
	 
	 	 	 	 
	Additional
Cash Compensation
	 	 	 	 
	Chair of Board
	 	$	100,000	 
	Chair of Audit Committee
	 	$	30,000	 
	Chair of Compensation Committee
	 	$	15,000	 
	Chair of Corporate Governance and Nominating Committee
	 	$	10,000	 
	Chair of All Other Committees
	 	$	10,000	 
	Member of Audit Committee
	 	$	15,000	 
	Member of Compensation Committee
	 	$	7,500	 
	Member of Corporate Governance and Nominating Committee
	 	$	5,000	 
	Member of All Other Committees (excluding the Executive Committee)
	 	$	5,000	 

Option Grants and Other Stock Awards:

Initial Grants

     Each non-employee director receives an initial grant of options to purchase 15,000 shares of
common stock and also receives an award of 5,000 shares of restricted stock, restricted stock units
or deferred stock units upon his or her initial election to the Board.

Annual Grants

     In addition to initial equity awards, non-employee directors receive annual equity grants.
Each non-employee director, not including the Chairman of the Board, receives options to purchase
7,500 shares of common stock and an award of 2,500 shares of restricted stock, restricted stock
units or deferred stock units upon each re-election for a one-year Board term, with the exception
of those directors who as of the 2008 Annual Meeting had not served three years on the Board. Such
directors receive an annual option to purchase 3,000 shares of common stock and an award of 1,500
shares of restricted stock, restricted stock units or deferred stock units until they have served
three years on

 

 

the Board, at which time they would receive the grants described above. The Chairman of the Board
receives options to purchase 10,000 shares of common stock and an award of 4,000 shares of
restricted stock, restricted stock units or deferred stock units upon re-election for a one-year
Board term.

Forms of Awards

     The restricted stock and restricted stock units represent the right of a director to receive
one share of OSI common stock upon vesting. Each deferred stock unit represents the right of a
director to receive one share of OSI common stock upon the earlier of the director’s termination
from service on the Board or on a date no earlier than two years from the date of grant, as
designated by the director.

     The stock option awards and restricted stock awards, including restricted stock units and
deferred stock units, granted to the directors after June 14, 2006 vest annually over four years of
the date of grant. The option awards expire on the seventh anniversary of their respective grant
dates, subject to the earlier expiration upon the occurrence of certain events set forth in the
Company’s Amended and Restated Stock Incentive Plan. The exercise price of all option awards is
equal to 100% of the fair market value of the underlying common stock on the date of grant.

Post-Retirement Medical Benefits:

     Prior to April 2007, we provided post-retirement medical and life insurance benefits to
eligible employees and qualified dependents, and members of our Board of Directors. Eligibility was
based on age and service requirements. These benefits are subject to deductibles, co-payment
provisions and other limitations. In April 2007, we terminated this benefit and grandfathered the
directors who were eligible for participation in the plan at the time of termination (Mr. White and
Drs. Mehta and Granner).

-2-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00153-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00153-of-00352.parquet"}]]